SCHEMBL2645002

SCHEMBL2645002

Cc1ccc(C(=O)COc2cc(C(=O)O)cc3c2CC(C)(C)O3)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 3/20 0.38
HPGD P15428 3/20 0.38
CASP1 P29466 3/20 0.38
HSD17B10 Q99714 3/20 0.38
GLA P06280 2/20 0.38
CASP7 P55210 2/20 0.38
CYP26A1 O43174 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP26B1 Q9NR63 1/20 0.36
GCK P35557 2/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTT P42858 1/20 0.34
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643330 0.83 KDM4E (0.39) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL644552 0.82 GCK (0.55) GCKNPC1RAB9A
SCHEMBL2644923 0.82 GCK (0.37) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2643933 0.78 TSHR (0.43) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2644213 0.76 IRAK4 (0.39) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2643648 0.76 KDM5A (0.41) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL643590 0.75 MAOB (0.49) HPGDNPC1RAB9AKMT2AMEN1
SCHEMBL2645457 0.73 KDM4A (0.37) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2643969 0.72 GSTP1 (0.41) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2645105 0.72 SMPD1 (0.35) ALDH1A1KDM4EGAAHPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 ALDH1A1 1370/4885KDM4E 1790/4885GAA 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.